Through its business entities, OneStudyTeam and Care Access, the company provides best-in-class trial optimization software and transformative clinical trial infrastructure that delivers research directly to more healthcare providers, communities, and patients wherever they are. Reify Health became a unicorn in 2021 and maintains focus on accelerating clinical trial operations while expanding access to underserved populations.
Cyborg Score Rationale
Reify Health demonstrates strong market positioning with significant funding, a $4.8B valuation, and clear product-market fit serving a critical need in clinical trial infrastructure. The company is executing a focused mission around trial optimization and accessibility, though as a private Series D company, revenue and profitability metrics remain opaque.
Top Insights
In November 2024, raised a $220 million Series D round co-led by Altimeter Capital and Coatue with participation from Dragoneer Investment Group, ICONIQ Growth and others
Using fresh funding to invest in improving clinical trial diversity and grow diversity within clinical trial studies for healthcare and life science industries
As of February 2026, the company has 73 employees
Platform consolidation through OneStudyTeam brand unifies fragmented clinical trial workflows across sponsors, sites, and patients
Named Competitors
Medidata — Clinical trial software and data analytics